Select your Background Color
add
add longest videos

Radafaxine is drug candidate designated GW-353,162 by GlaxoSmithKline, investigated for treatment of restless leg syndrome and as an NDRI antidepressant. GlaxoSmithKline was targeting Radafaxine for regulatory filing in 2007, but development was discontinued in 2006 due to "poor test results".

It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's Wellbutrin. More specifically, "6-hydroxybupropion" is an analogue of bupropion, and radafaxine is an isolated isomer of 6-hydroxybupropion.

Therefore, radafaxine builds on at least some of the properties of bupropion in humans.

In various clinical trials, radafaxine has been studied as a treatment for clinical depression, obesity, and neuropathic pain. Radafaxine is described as a norepinephrine-dopamine reuptake inhibitor (NDRI).

Unlike bupropion (which has a slightly higher effect on dopamine reuptake), radafaxine seems to have a higher potency on norepinephrine. This, according to GlaxoSmithKline, may account for the increased effect of radafaxine on pain and fatigue.

Read more...



This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Radafaxine

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.









×
×